Recent Quotes (30 days)

You have no recent quotes
chg | %

ProMetic Life Sciences Inc.  

(Public, TSE:PLI)   Watch this stock  
Find more results for PLI
1.55
-0.07 (-4.32%)
Delayed:   10:35AM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.49 - 1.61
52 week 1.12 - 3.24
Open 1.61
Vol / Avg. 354,180.00/1.52M
Mkt cap 1.10B
P/E     -
Div/yield     -
EPS -0.19
Shares 706.75M
Beta 2.23
Inst. own     -
Sep 25, 2017
Prometic Life Sciences Inc at Cantor Fitzgerald Global Healthcare Conference
Sep 11, 2017
Prometic Life Sciences Inc at Morgan Stanley Healthcare Conference - Webcast
Aug 15, 2017
Q2 2017 Prometic Life Sciences Inc Earnings Call
Aug 10, 2017
Prometic Life Sciences Inc at Canaccord Genuity Growth Conference
  

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -870.60% -675.14%
Operating margin -841.31% -682.88%
EBITD margin - -637.46%
Return on average assets -50.15% -46.06%
Return on average equity -101.57% -82.05%
Employees 389 -
CDP Score - -

Address

440 Armand-Frappier Blvd Suite 300
LAVAL, QC H7V 4B4
Canada
+1-450-7810115 (Phone)
+1-450-7814477 (Fax)

Website links

Description

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs. ProMetic is also developing its own small molecule therapeutic products targeting unmet medical needs in the field of fibrosis, autoimmune disease/inflammation and cancer. It has research and development facilities in the United Kingdom, the United States and Canada; manufacturing facilities in the Isle of Man and Canada, and business development activities in the United States, Europe and Asia.

Officers and directors

Simon Geoffrey Best Independent Chairman of the Board
Age: 60
Pierre Laurin Ph.D. President, Chief Executive Officer, Non-Independent Director
Age: 56
Bruce Pritchard Interim Chief Financial Officer, Chief Operating Officer
John Moran M.D. Chief Medical Officer, Director
Age: 71
Patrick Sartore Chief Legal Officer and Corporate Secretary
Stefan Clulow Non-Independent Director
Age: 46
Charles N. Kenworthy Non-Independent Director
Age: 58
Bruce J. Wendel Non-Independent Director
Age: 63
Andrew Bishop Independent Director
Kenneth H. Galbraith Independent Director
Age: 54